EP4367252A4 - Pharmazeutische zusammensetzung eines nichtumhüllten virus - Google Patents

Pharmazeutische zusammensetzung eines nichtumhüllten virus

Info

Publication number
EP4367252A4
EP4367252A4 EP22838112.5A EP22838112A EP4367252A4 EP 4367252 A4 EP4367252 A4 EP 4367252A4 EP 22838112 A EP22838112 A EP 22838112A EP 4367252 A4 EP4367252 A4 EP 4367252A4
Authority
EP
European Patent Office
Prior art keywords
pharmaceutical composition
enveloped virus
enveloped
virus
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP22838112.5A
Other languages
English (en)
French (fr)
Other versions
EP4367252A2 (de
Inventor
Lina Igorevna FEDORENKO
Ekaterina Aleksandrovna LOMKOVA
Aleksandr Olegovich IAKOVLEV
Aleksandra Aleksandrovna SOZONOVA
Marina Konstantinovna DVORIANKINA
Dmitry Valentinovich MOROZOV
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biocad JSC
Original Assignee
Biocad JSC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2021120143A external-priority patent/RU2021120143A/ru
Application filed by Biocad JSC filed Critical Biocad JSC
Publication of EP4367252A2 publication Critical patent/EP4367252A2/de
Publication of EP4367252A4 publication Critical patent/EP4367252A4/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Inorganic Chemistry (AREA)
  • Mycology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
EP22838112.5A 2021-07-08 2022-07-04 Pharmazeutische zusammensetzung eines nichtumhüllten virus Pending EP4367252A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2021120143A RU2021120143A (ru) 2021-07-08 Фармацевтическая композиция безоболочечного вируса
PCT/RU2022/050212 WO2023282796A2 (en) 2021-07-08 2022-07-04 Pharmaceutical composition of non-enveloped virus

Publications (2)

Publication Number Publication Date
EP4367252A2 EP4367252A2 (de) 2024-05-15
EP4367252A4 true EP4367252A4 (de) 2025-04-30

Family

ID=84800844

Family Applications (1)

Application Number Title Priority Date Filing Date
EP22838112.5A Pending EP4367252A4 (de) 2021-07-08 2022-07-04 Pharmazeutische zusammensetzung eines nichtumhüllten virus

Country Status (12)

Country Link
EP (1) EP4367252A4 (de)
CN (1) CN117999353A (de)
AR (1) AR126417A1 (de)
CL (1) CL2024000062A1 (de)
CO (1) CO2024000073A2 (de)
CR (1) CR20240004A (de)
EC (1) ECSP24001599A (de)
JO (1) JOP20240003A1 (de)
MA (1) MA63861A1 (de)
MX (1) MX2024000472A (de)
WO (1) WO2023282796A2 (de)
ZA (1) ZA202400124B (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2026503893A (ja) * 2023-01-19 2026-02-02 ユニキュアー バイオファーマ ビー．ブイ． 遺伝子送達媒体の医薬製剤
TW202525313A (zh) * 2023-09-06 2025-07-01 瑞士商迪納柯公司 用ａａｖ基因治療載體及治療調配物治療肥厚性心肌病之方法
WO2025114524A1 (en) * 2023-11-30 2025-06-05 Uniqure Biopharma B.V. Formulations for viral drug products
WO2025263459A1 (ja) * 2024-06-17 2025-12-26 学校法人神戸薬科大学 バイオ医薬品組成物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130216499A1 (en) * 2012-02-17 2013-08-22 Wenlin Huang Compositions of recombinant human endostatin adenovirus injections and methods of production
WO2015040002A1 (en) * 2013-09-19 2015-03-26 Crucell Holland B.V. Improved adenovirus formulations
WO2018128689A1 (en) * 2016-11-04 2018-07-12 Baxalta Incorporated Adeno-associated virus formulations

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012222150A1 (en) * 2011-02-24 2013-09-26 Paxvax, Inc. Formulations useful for spray drying vaccines
CA3107462A1 (en) * 2018-07-24 2020-01-30 Voyager Therapeutics, Inc. Systems and methods for producing gene therapy formulations

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130216499A1 (en) * 2012-02-17 2013-08-22 Wenlin Huang Compositions of recombinant human endostatin adenovirus injections and methods of production
WO2015040002A1 (en) * 2013-09-19 2015-03-26 Crucell Holland B.V. Improved adenovirus formulations
WO2018128689A1 (en) * 2016-11-04 2018-07-12 Baxalta Incorporated Adeno-associated virus formulations

Also Published As

Publication number Publication date
ZA202400124B (en) 2024-11-27
EP4367252A2 (de) 2024-05-15
JOP20240003A1 (ar) 2024-01-08
MA63861A1 (fr) 2024-10-31
CR20240004A (es) 2024-06-11
CL2024000062A1 (es) 2024-06-14
CN117999353A (zh) 2024-05-07
CO2024000073A2 (es) 2024-04-29
ECSP24001599A (es) 2024-02-29
WO2023282796A3 (en) 2023-02-16
MX2024000472A (es) 2024-02-12
WO2023282796A2 (en) 2023-01-12
AR126417A1 (es) 2023-10-11

Similar Documents

Publication Publication Date Title
EP4367252A4 (de) Pharmazeutische zusammensetzung eines nichtumhüllten virus
EP3914252A4 (de) Pharmazeutische zusammensetzung von nilotinib
DK4445900T3 (da) Terapeutiske forbindelser til hiv-virusinfektion
EP3996716C0 (de) Verbindungen zur behandlung von influenzavirus-infektionen
EP3981390A4 (de) Pharmazeutische lacosamid-zusammensetzung und pharmazeutisches präparat daraus
EP4028059A4 (de) Stabile medizinische cannabidiolzusammensetzungen
EP3906019C0 (de) Pharmazeutische zusammensetzungen von furosemid
EP4073071A4 (de) Verwendung und pharmazeutische zusammensetzung von phenylisoxazolylmethylen-naphthalen-ether-derivaten
EA201792008A1 (ru) Соединения азапиридона и способы их применения
EP3946316A4 (de) Pharmazeutische cannabidiolzusammensetzungen
EP4415708A4 (de) Zusammensetzungen zur verabreichung von cannabinoiden
EP4122483A4 (de) Orale pharmazeutische zusammensetzung
EP4023227A4 (de) Pharmazeutische zusammensetzung und verabreichung davon
EP3777866A4 (de) Pharmazeutische zusammensetzung und verabreichung davon
EP4508077A4 (de) Zusammensetzungen zur prävention oder behandlung von influenza-infektionen
EP3741845A4 (de) Rekombinantes vaccinia-virus und pharmazeutische zusammensetzung damit
EP3582759A4 (de) Bioäquivalente pharmazeutische zusammensetzung von vortioxetinhydrobromid
EP4456887A4 (de) Pharmazeutische zusammensetzung
EP3399040A4 (de) Verfahren zur herstellung eines capsidproteins des schweine-circovirus vom typ 2 und pharmazeutische zusammensetzung damit
EP3880183A4 (de) Pharmazeutische zubereitung von fruquintinib und verwendung davon
CR20240192A (es) Composiciones farmacéuticas de efruxifermina
EP4275007C0 (de) Trocknung von pharmazeutischen pulvern
DOP2025000121A (es) Composición farmacéutica de virus sin envoltura
EP4452295A4 (de) Pharmazeutische zusammensetzung zur behandlung von virusinfektionen
EP4176868A4 (de) Stabile pharmazeutische zusammensetzung

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20231221

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20250402

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 47/10 20170101ALI20250327BHEP

Ipc: A61K 9/00 20060101ALI20250327BHEP

Ipc: A61K 47/02 20060101ALI20250327BHEP

Ipc: A61K 47/40 20060101ALI20250327BHEP

Ipc: A61K 47/34 20170101ALI20250327BHEP

Ipc: A61K 47/26 20060101ALI20250327BHEP

Ipc: A61K 47/18 20170101ALI20250327BHEP

Ipc: A61K 9/19 20060101ALI20250327BHEP

Ipc: A61K 9/08 20060101ALI20250327BHEP

Ipc: A61K 35/76 20150101ALI20250327BHEP

Ipc: C12N 7/00 20060101ALI20250327BHEP

Ipc: C12N 15/86 20060101AFI20250327BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20251216